Literature DB >> 32324262

LINC02535 co-functions with PCBP2 to regulate DNA damage repair in cervical cancer by stabilizing RRM1 mRNA.

Danxia Wen1, Zhong Huang2, Zhouyu Li1, Xi Tang1, Xiaomin Wen1, Jinquan Liu1, Mingyi Li1.   

Abstract

Cervical cancer (CC) is one of the commonest malignant cancers among women with high morbidity and mortality. Despite encouraging advances had been found in diagnostic and therapeutic strategies, effective therapeutic strategy and further exploration of the mechanism underlying in CC is still needed. We searched The Cancer Genome Atlas database and found that long noncoding RNA LINC02535 was highly expressed in CC. LINC02535 has not been studied in CC, and its molecular regulation mechanism remains unknown. Based on starBase database, LINC02535 could potentially bind poly (rC) binding protein 2 (PCBP2). In the present study, we discovered a significant increase of the LINC02535 and PCBP2 expression in CC tissues and cells as compared with the adjacent normal tissues and normal cervical epithelial cells. LINC02535 and PCBP2 can bind with each other and were colocated in cytoplasm. LINC02535 and PCBP2 promoted cell proliferation, migration, invasion, and suppressed apoptosis in CC. LINC02535 and PCBP2 facilitated the repair of DNA damage to promote CC progression. LINC02535 cooperated with PCBP2 to enhance the stability of RRM1 messenger RNA (mRNA). RRM1 promoted the repair of DNA damage and epithelial-to-mesenchymal transition (EMT) process in CC cells. LINC02535 regulated tumorigenesis in vivo. In conclusion, LINC02535 cooperated with PCBP2, regulated stability of RRM1 mRNA to promote cell proliferation and EMT process in CC cells by facilitating the repair of DNA damage, providing a potential biomarker for CC.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  LINC02535; PCBP2; RRM1; cervical cancer

Year:  2020        PMID: 32324262     DOI: 10.1002/jcp.29667

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  8 in total

1.  Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.

Authors:  Yue Li; Ruoyi Shen; Anqi Wang; Jian Zhao; Jieqi Zhou; Weijie Zhang; Ruochen Zhang; Jianjie Zhu; Zeyi Liu; Jian-An Huang
Journal:  Front Cell Dev Biol       Date:  2021-03-18

2.  A Novel Ferroptosis-Related lncRNA Signature for Prognosis Prediction in Patients with Papillary Renal Cell Carcinoma.

Authors:  Ruijie Dang; Meiling Jin; Jingzhu Nan; Xuege Jiang; Zheng He; Fang Su; Diangeng Li
Journal:  Int J Gen Med       Date:  2022-01-06

3.  Comprehensive Analysis of Sinonasal Inverted Papilloma Expression Profiles Identifies Long Non-Coding RNA AKTIP as a Potential Biomarker.

Authors:  Hanyi He; Xinlu Wang; Yueyue Lu; Xiaojiang Lin; Yuandong Li; Yong Li; Zhihong Lin; Zhiqi Ma; Xiaolin Cao; Yaoshu Teng
Journal:  Front Genet       Date:  2022-02-02       Impact factor: 4.599

Review 4.  The Regulatory Functions and the Mechanisms of Long Non-Coding RNAs in Cervical Cancer.

Authors:  Qiwei Yang; Ayman Al-Hendy
Journal:  Cells       Date:  2022-03-29       Impact factor: 6.600

5.  Identification of the Ferroptosis-Related Long Non-Coding RNAs Signature to Improve the Prognosis Prediction in Papillary Renal Cell Carcinoma.

Authors:  Xinfang Tang; Feng Jiang; Xiaoyu Wang; Ying Xia; Yan Mao; Yan Chen
Journal:  Front Surg       Date:  2022-03-04

6.  PHGDH Inhibits Ferroptosis and Promotes Malignant Progression by Upregulating SLC7A11 in Bladder Cancer.

Authors:  Liliang Shen; Junfeng Zhang; Zongtai Zheng; Fuhan Yang; Shenghua Liu; Yuan Wu; Yifan Chen; Tianyuan Xu; Shiyu Mao; Yang Yan; Wei Li; Wentao Zhang; Xudong Yao
Journal:  Int J Biol Sci       Date:  2022-08-29       Impact factor: 10.750

7.  Iron as spirit of life to share under monopoly.

Authors:  Shinya Toyokuni; Yingyi Kong; Hao Zheng; Yuki Maeda; Yashiro Motooka; Shinya Akatsuka
Journal:  J Clin Biochem Nutr       Date:  2022-07-27       Impact factor: 3.179

8.  LINC02535 promotes cell growth in poorly differentiated gastric cancer.

Authors:  Jianzhong Wu; Ling Gao; Hong Chen; Xiaojun Zhou; Xialiang Lu; Zhongqi Mao
Journal:  J Clin Lab Anal       Date:  2021-06-14       Impact factor: 2.352

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.